Published in Semin Oncol on June 01, 1977
Increasing the benefits of chemotherapy by ameliorating the adverse effects. Can Fam Physician (1987) 0.75
A fluorimetric study of the hydroxylation of biphenyl in vitro by liver preparations of various species. Biochem J (1965) 2.47
A spectrofluorimetric study of the 7-hydroxylation of coumarin by liver microsomes. Biochem J (1965) 1.76
Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. J Clin Oncol (1998) 1.72
The fluorescence of some biphenyl derivatives. Biochem J (1965) 1.47
In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res (1993) 1.37
Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. Cancer Chemother Rep (1972) 1.32
Intensive chemotherapy of small cell bronchogenic carcinoma. Cancer Treat Rep (1977) 1.29
Combined effects of chemotherapy and immunity against leukemia L1210 in DBA-2 mice. Cancer Res (1969) 1.26
Specific inhibition of the enzymic decarboxylation of S-adenosylmethionine by methylglyoxal bis(guanylhydrazone) and related substances. Biochem J (1974) 1.15
Clinical pharmacological studies of concurrent infusion of 5-fluorouracil and thymidine in treatment of colorectal carcinomas. Cancer Res (1982) 1.14
Pharmacokinetic and pharmacodynamic studies of N-acetylcysteine, a potential chemopreventive agent during a phase I trial. Cancer Epidemiol Biomarkers Prev (1995) 1.12
The stimulation of hydroxylation by carcinogenic and non-carcinogenic compounds. Biochem Pharmacol (1966) 1.09
Metabolism of tyramine-1-14C by the rat. Biochem Pharmacol (1970) 1.09
Treatment of acute nonlymphocytic leukemia: use of anthracycline-cytosine arabinoside induction therapy and comparison of two maintenance regimens. Blood (1979) 1.03
Ethanol oxidation in the microsomal fraction of rat liver. Biochem Biophys Res Commun (1969) 1.02
Prostaglandin modulation of development of cell-mediated immunity in culture. Nature (1980) 1.00
Modification of tumor regression by immunologic means. Cancer Res (1969) 0.99
Evidence for the involvement of ecto-5'-nucleotidase (CD73) in drug resistance. Int J Cancer (1996) 0.99
Studies on the human pharmacokinetics of isophosphamide (NSC-109724). Cancer Treat Rep (1976) 0.98
Growth of cell colonies in soft agar from biopsies of different human solid tumors. Cancer Res (1980) 0.98
Studies on the clinical pharmacology and toxicology of isophosphamide (NSC-109724). Cancer Treat Rep (1976) 0.98
Role of tumor necrosis factor in macrophage activation and tumoricidal activity. Cancer Res (1988) 0.97
Initial clinical (phase I) trial of TLC D-99 (doxorubicin encapsulated in liposomes). Cancer Res (1993) 0.96
Cytotoxicity, cellular accumulation and DNA binding of oxaliplatin isomers. Cancer Lett (1995) 0.96
Pharmacokinetics of divided-dose ifosfamide. Clin Pharmacol Ther (1976) 0.96
Colony growth in soft agar of human melanoma, sarcoma, and lung carcinoma cells disaggregated by mechanical and enzymatic methods. Cancer Res (1980) 0.96
Characterization of cells obtained by mechanical and enzymatic means from human melanoma, sarcoma, and lung tumors. Cancer Res (1981) 0.95
Phase I-II trial of high-dose calcium leucovorin and 5-fluorouracil in advanced colorectal cancer. Cancer Res (1984) 0.95
Altered glutathione metabolism in oxaliplatin resistant ovarian carcinoma cells. Cancer Lett (1996) 0.94
Effect of recombinant tumor necrosis factor on tumoricidal activation of murine macrophages: synergism between tumor necrosis factor and gamma-interferon. Cancer Res (1987) 0.93
Tumoricidal activation of murine resident peritoneal macrophages by interleukin 2 and tumor necrosis factor alpha. Cancer Res (1992) 0.91
Phase I clinical trial of cis-dichloro-trans-dihydroxy-bis-isopropylamine platinum(IV) (CHIP). Cancer Treat Rep (1983) 0.91
The clinical pharmacology of VM26 and VP16-213. A brief overview. Cancer Chemother Pharmacol (1982) 0.91
Plasma and tumor tissue pharmacology of high-dose intravenous leucovorin calcium in combination with fluorouracil in patients with advanced colorectal carcinoma. J Clin Oncol (1988) 0.91
Antibacterial properties of eight dental cements. Int Endod J (1993) 0.90
Plasma camptothecin (NSC-100880) levels during a 5-day course of treatment: relation to dose and toxicity. Cancer Chemother Rep (1972) 0.89
Cell population kinetics of fast- and slow-growing transplantable tumors derived from spontaneous mammary tumors of the DBA/2 Ha-DD mouse. Cancer Res (1978) 0.89
Role of tumor necrosis factor and interleukin 1 in gamma-interferon-promoted activation of mouse tumoricidal macrophages. Cancer Res (1989) 0.89
Adriamycin-induced modulation of host defenses in tumor-bearing mice. Cancer Res (1992) 0.88
Increased primary cell-mediated immunity in culture subsequent to adriamycin or daunorubicin treatment of spleen donor mice. Cancer Res (1977) 0.88
Effects of anticancer drugs on the immune system in humans. Semin Oncol (1989) 0.88
Ecto-5'-nucleotidase (CD73) in multidrug-resistant cell lines generated by doxorubicin. Int J Cancer (1994) 0.88
Preliminary observations on the metabolism of (1- 14 C)tyramine in man. J Pharm Pharmacol (1972) 0.88
Biologic-response modifiers and adjuvant chemotherapy: consideration of selected preclinical investigations in relation to clinical potential. Recent Results Cancer Res (1982) 0.87
Toxicological and antiproliferative effects of N6-(delta2-isopentenyl) adenosine, a natural component of mammalian transfer RNA. Cancer Res (1970) 0.87
Daily subcutaneous injection of low-dose interleukin 2 expands natural killer cells in vivo without significant toxicity. Clin Cancer Res (1996) 0.87
Alteration in tyramine metabolism by ethanol. Biochem Pharmacol (1970) 0.87
Immunosuppressive effects of methylglyoxal-bis(guanylhydrazone) on mouse bone marrow and spleen cells and their antagonism by spermidine. Biochem Pharmacol (1978) 0.87
Protective specific immunity induced by doxorubicin plus TNF-alpha combination treatment of EL4 lymphoma-bearing C57BL/6 mice. Int J Cancer (2000) 0.87
The effect of butylated hydroxytoluene, butylated hydroxyanisole and octyl gallate upon liver weight and biphenyl 4-hydroxylase activity in the rat. J Pharm Pharmacol (1966) 0.87
The effect of chloral hydrate on the metabolism of ethanol in mice. J Pharm Pharmacol (1969) 0.86
Identification of cis-dichloro-bis-isopropylamine platinum(II) as a major metabolite of iproplatin in humans. Cancer Res (1988) 0.86
Correlation between adriamycin-induced augmentation of interleukin 2 production and of cell-mediated cytotoxicity in mice. Cancer Res (1986) 0.86
DNA binding of iproplatin and its divalent metabolite cis-dichloro-bis-isopropylamine platinum (II). Cancer Chemother Pharmacol (1990) 0.86
Dealkylation of alkoxybiphenyls by trout and frog liver preparations. Life Sci (1967) 0.86
A novel tumor necrosis factor-alpha inhibitory protein, TIP-B1. Int J Immunopharmacol (2000) 0.85
Comparison of the human pharmacokinetics of VM-26 and VP-16, two antineoplastic epipodophyllotixin glucopyranoside derivatives. Eur J Cancer (1975) 0.85
Modification of host antitumor defense mechanisms in mice by progressively growing tumor. Cancer Res (1989) 0.85
Doxorubicin-induced DNA degradation in murine thymocytes. Mol Pharmacol (1994) 0.85
Translational studies of glutathione in bladder cancer cell lines and human specimens. Clin Cancer Res (1997) 0.85
A phase I and pharmacokinetic study of oral uracil, ftorafur, and leucovorin in patients with advanced cancer. Cancer Chemother Pharmacol (1996) 0.84
Selective modulation by alpha-difluoromethylornithine of T-lymphocyte and antibody-mediated cytotoxic responses to mouse tumor allografts. Cancer Res (1986) 0.84
Biochemical and pharmacologic basis for potentiation of 5-fluorouracil action by leucovorin. NCI Monogr (1987) 0.84
A micro-method for the determination of acetaldehyde and ethanol in blood. Clin Chim Acta (1968) 0.84
Intracellular glutathione and cytotoxicity of platinum complexes. Cancer Chemother Pharmacol (1995) 0.83
Doxorubicin plus tumor necrosis factor alpha combination treatments in EL4-lymphoma-bearing C57BL/6 mice. Cancer Immunol Immunother (1998) 0.83
Pharmacokinetics of ifosfamide. Clin Pharmacol Ther (1975) 0.83
Metastatic colorectal cancer: advances in biochemical modulation and new drug development. Semin Oncol (1995) 0.83
Expression, tissue distribution, and cellular localization of the antiapoptotic TIP-B1 protein. J Leukoc Biol (2001) 0.83
Effect of microsomal activation on interaction between isophosphamide and DNA. J Pharm Sci (1972) 0.82
Methotrexate in liver and bile after intravenous dosage in man. Br J Cancer (1973) 0.82
S-phase modulation by irinotecan: pilot studies in advanced solid tumors. Cancer Chemother Pharmacol (2005) 0.82
Fast- and slow-growing transplantable tumors derived from spontaneous mammary tumors of the DBA/2 Ha-DD mouse. Cancer Res (1975) 0.82
The effect of carcinogenic and noncarcinogenic compounds on the O-dealkylating activity of the hepatic microsomal enzyme system of the rat. Biochem Pharmacol (1967) 0.82
Effects of prostaglandins on the development of cell-mediated immunity in culture and on the cytolytic activity of in vivo-generated effector cells. Int J Immunopharmacol (1982) 0.81
Clinical pharmacology of isophosphamide. Clin Pharmacol Ther (1974) 0.81
Alterations in murine host defense functions by adriamycin or liposome-encapsulated adriamycin. Cancer Res (1988) 0.81
Effect of splenectomy on the regression of transplantable tumors. Cancer Res (1968) 0.81
Adriamycin induced immunomodulation: dependence upon time of administration. Int J Immunopharmacol (1983) 0.81
Modulation of the development of cell-mediated immunity: possible role of the products of the cyclo-oxygenase and the lipoxygenase pathways of arachidonic acid metabolism. Int J Immunopharmacol (1982) 0.81
Kinetic model for the disposition and metabolism of moderate and high-dose methotrexate (NSC-740) in man. Cancer Chemother Rep (1975) 0.80
Specific anti-EL4-lymphoma immunity in mice cured 2 years earlier with doxorubicin and interleukin-2. Cancer Immunol Immunother (1996) 0.80
Antigenic differences between leukemia L1210 and a subline resistant to methylglyoxal-bis(guanylhydrazone). Cancer Res (1972) 0.80
Pharmacokinetics of methotrexate following intravenous and intraventricular administration in acute lymphocytic leukemia and non-Hodgkin's lymphoma. Cancer (1982) 0.80
Uptake and metabolism of iproplatin in murine L1210 cells. Cancer Chemother Pharmacol (1989) 0.80
Phase I/pharmacodynamic study of N-acetylcysteine/oltipraz in smokers: early termination due to excessive toxicity. Cancer Epidemiol Biomarkers Prev (2001) 0.80
Plasma membrane as a site for chemotherapeutic intervention. Adv Enzyme Regul (1978) 0.80
Cyclophosphamide plus tumor necrosis factor-alpha chemoimmunotherapy cured mice: life-long immunity and rejection of re-implanted primary lymphoma. Int J Cancer (1995) 0.80
Effect of tranylcypromine sulphate on the metabolism of ( 14 C)tyramine in vivo in the rat. J Pharm Pharmacol (1972) 0.80
Toxic and patologic effects of 4,4'-diacetyl-diphenyl-urea-bis(guanylhydrazone), a new antileukemic agent. Cancer Res (1969) 0.79
Lipopolysaccharide and splenic tumoricidal macrophage activation. J Leukoc Biol (1994) 0.79
Changes in cytosolic and membrane TNF inhibitory protein-B1 (TIP-B1) levels associated with protection from TNF-induced cytotoxicity. FASEB J (2001) 0.79
Octreotide does not prevent diarrhea in patients treated with weekly 5-fluorouracil plus high-dose leucovorin. Am J Clin Oncol (1998) 0.79
Thymic anti-tumor effectors in mice cured of lymphoma by cyclophosphamide plus TNF-alpha therapy: phenotypic and functional characterization up to 20 months after initial tumor inoculation. Int J Cancer (1998) 0.79
Phase I-II evaluation of emetine (NSC-33669) in the treatment of epidermoid bronchogenic carcinoma. Cancer Chemother Rep (1976) 0.79
Comparison of adriamycin induced immunomodulation with that of the noncardiotoxic anthracycline 5-iminodaunorubicin. Int J Immunopharmacol (1988) 0.79
Comparative study of the toxicologic effects of 7-deazaadenosine (tubercidin) and 7-deazainosine. Cancer Res (1969) 0.79
Activation of the antineoplastic drug isophosphamide by rat liver microsomes. J Pharm Pharmacol (1972) 0.79
Lack of effect of treatment with human recombinant-tumour necrosis factor (HrTNF) on the binding of quinidine to alpha 1-acid glycoprotein (AGP). Br J Clin Pharmacol (1989) 0.79